Telaprevir- and boceprevir-based triple therapy for hepatitis C in liver transplant recipients with advanced recurrent disease: A multicenter study

Medicine & Life Sciences

• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 100%
• telaprevir 96%
• Hepatitis C 65%
• Hepatitis 60%
• Transplant Recipients 59%
• Liver Transplantation 58%
• Multicenter Studies 55%
• Fibrosis 47%
• Sustained Virologic Response 34%
• Genotype 27%
• Protease Inhibitors 26%
• Hispanic Americans 24%
• Hepacivirus 23%
• Safety 22%
• Albumins 21%
• Odds Ratio 16%
• Platelet Count 12%
• Brain Diseases 12%
• Antiviral Agents 10%
• Therapeutics 10%
• Steroids 9%
• Survival 7%
• Liver 6%